In formulas containing many components, literature on individual ingredients does not necessarily describe the behaviour of the finished matrix. Dose, chemical forms, absorption competition, excipients and administration can alter exposure.

The AG1 trial addresses the first measurable clinical level: plasma appearance of selected micronutrients after a single dose. It is acute bioavailability evidence, distinct from correcting deficiency or improving health.

A robust strategy advances through levels: formulation characterisation and stability, pharmacokinetics or bioavailability, change in nutritional status, functional endpoints, duration, safety and comparison with placebo or simpler interventions.

This pathway anchors the message to the formula actually sold. It also prevents an absorption signal from becoming, without intermediate evidence, a general efficacy promise.

Why it matters

For scientific marketing and product development, testing the finished formula captures matrix interactions without confusing acute absorption with clinical efficacy.

Evidence limit

Methodological analysis of the AG1 study reported on 30 July. The trial measures eight-hour exposure after one dose in 16 healthy adults, not chronic clinical benefit.

Editorial note. This content is intended for industry professionals. It does not constitute medical advice, therapeutic guidance or regulatory advice. Read our editorial method.

Read the original source · Frontiers in Nutrition ↗